(Q46037972)

18 December 2017

title

Treatment of acromegaly with a somatostatin analog in a patient with McCune-Albright syndrome. (English)

1 reference

18 December 2017

author name string

Geffner ME

1

1 reference

18 December 2017

Nagel RA

2

1 reference

18 December 2017

Dietrich RB

3

1 reference

18 December 2017

Kaplan SA

4

1 reference

18 December 2017

language of work or name

English

0 references

publication date

1 November 1987

1 reference

18 December 2017

The Journal of Pediatrics

published in

1 reference

18 December 2017

volume

111

1 reference

18 December 2017

issue

5

1 reference

18 December 2017

page(s)

740-743

1 reference

18 December 2017

Letter: Pituitary adenoma in McCune-Albright syndrome: follow-up information

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980258-5

McCune-Albright syndrome associated with a functioning pituitary chromophobe adenoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980258-5

Gigantism and hyperprolactinemia in polyostotic fibrous dysplasia (Mc Cune--Albright syndrome)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980258-5

Treatment of juvenile acromegaly with bromocriptine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980258-5

Gigantism associated with McCune-Albright's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980258-5

Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980258-5

Effect of somatostatin in patients with acromegaly: suppression of growth hormone, prolactin, insulin and glucose levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980258-5

Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980258-5

The response of serum growth hormone levels to the long-acting somatostatin analog SMS 201-995 in acromegaly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980258-5

Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980258-5

Extrahypothalamic growth-hormone-releasing factor (GRF) secretion is a rare cause of acromegaly: plasma GRF levels in 177 acromegalic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980258-5

Effect of oral glucose administration on plasma growth hormone-releasing hormone (GHRH)-like immunoreactivity levels in normal subjects and patients with idiopathic GH deficiency: evidence that GHRH is released not only from the hypothalamus but als

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980258-5

McCune-Albright syndrome. Long-term follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980258-5

The McCune-Albright syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980258-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Acromegaly and hyperprolactinemia in McCune-Albright syndrome. Evidence of hypothalamic dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980258-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-3476(87)80258-5

1 reference

18 December 2017

1 reference

18 December 2017